2016•Int J Endocrinol MetabRequires access
Drug treatment of congenital nephrogenic diabetes insipidus
Weihong Guo, Qiang Li
Open publisher page 0 citations
Abstract
Congenital nephrogenic diabetes insipidus is caused by mutations of Arginine vasopressin receptor 2(AVPR2)/Auqaporin-2(AQP2). The current clinical treatment is aimed at improving symptoms of polydipsia, polyuria. With the deepening research on the pathogenesis, AVPR2 agonists and antagonists, phosphodiesterase antagonists, statins, prostaglandin E receptor agonists can improve mutational AVPR2/AQP2 in synthesis, modification, expression in cells, so achieve the goal of treatment.
Key words:
Congenital nephrogenic diabetes insipidus; Arginine vasopressin receptor 2; Auqaporin-2